Therapeuticsmd Inc Stock Price, News & Analysis

TherapeuticsMD, Inc. (NASDAQ: TXMD) has announced its fourth quarter 2020 financial results reporting on Tuesday, March 2, 2021, before U.S. market opening. The company will hold a conference call at 8:30 a.m. ET to discuss the results and provide a business update. Interested parties can access the call via telephone at 866-665-9531 for U.S. callers or 724-987-6977 for international calls, using access code 6184646. The event will also be available via a live audio webcast on their website.

TherapeuticsMD, Inc. (NASDAQ:TXMD) has successfully closed its underwritten public offering of 59,459,460 shares of common stock, generating approximately $97.1 million in net proceeds. The offering was fully sold by TherapeuticsMD, which has also granted the underwriter a 30-day option to acquire up to 8.9 million additional shares. Cantor Fitzgerald & Co. served as the sole bookrunning manager. This follows a previously effective shelf registration statement filed with the SEC.

TherapeuticsMD, Inc. (NASDAQ:TXMD) announced an underwritten public offering of approximately 59.5 million shares at a gross proceeds of $110 million, closing expected around February 16, 2021. Cantor Fitzgerald & Co. is the bookrunning manager, with a 30-day option for the underwriter to purchase an additional 8.9 million shares. Proceeds will be used for commercialization of FDA-approved products like IMVEXXY®, BIJUVA®, and ANNOVERA®, along with debt discharge and working capital.

TherapeuticsMD, Inc. (NASDAQ:TXMD) has announced an underwritten public offering of its common stock, allowing the underwriter a 30-day option to purchase an additional 15% of offered shares. All shares will be sold by the company, with Cantor Fitzgerald & Co. serving as the sole bookrunning manager. Proceeds from the offering are intended for commercialization of three FDA-approved products: IMVEXXY®, BIJUVA®, and ANNOVERA®, as well as to reduce existing debt and general corporate purposes.

TherapeuticsMD, Inc. (NASDAQ: TXMD) will participate in two upcoming investor conferences: the H.C. Wainwright BioConnect Conference from January 11-14, 2021, and the J.P. Morgan Virtual Healthcare Conference on January 14, 2021, at 8:20 a.m. Eastern time. Presentations will be available online during the events. TherapeuticsMD specializes in women’s healthcare, focusing on products for family planning, reproductive health, and menopause management. For more details, visit therapeuticsmd.com.

TherapeuticsMD (NASDAQ:TXMD) has launched Just Say Vagina, a campaign aimed at empowering women to openly discuss reproductive health issues. Comedian Whitney Cummings, who has utilized the ANNOVERA® contraceptive, will be featured, encouraging women to abandon euphemisms in favor of direct communication about their needs. The press release highlights that 45% of unintended pregnancies in the U.S. stem from inconsistent contraceptive use, and 47% of women discontinue birth control due to dissatisfaction.

TherapeuticsMD, Inc. (NASDAQ:TXMD) has successfully closed an underwritten public offering of 23,437,500 shares of its common stock, generating net proceeds of approximately $27.5 million after deducting underwriting discounts and commissions. All shares were sold by TherapeuticsMD, with Cantor Fitzgerald & Co. serving as the sole bookrunning manager. The offering was conducted under a previously declared effective shelf registration statement with the SEC.

TherapeuticsMD, Inc. (NASDAQ: TXMD) announced its participation in the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 9:20 a.m. Eastern time. Investors can access a live webcast of the presentation on the company’s website. TherapeuticsMD focuses on developing innovative products for women's healthcare, addressing issues in family planning, reproductive health, and menopause management. The company aims to enhance women’s health and raise awareness of their healthcare challenges.

TherapeuticsMD (NASDAQ:TXMD) announced the pricing of its public offering of approximately 23.4 million shares, aiming for gross proceeds of $30 million. The offering is set to close around November 12, 2020, pending customary conditions. A 30-day option for underwriters to purchase an additional 3.5 million shares is also granted. The proceeds will fund the commercialization of three FDA-approved products: IMVEXXY, BIJUVA, and ANNOVERA, as well as working capital and general corporate purposes.